Financials

MDxHealth operates on a calendar basis with its accounting year ending on December 31.

The company reports its consolidated financial statements under International Financial Reporting Standards (IFRS) and all amounts are in US Dollars. MDxHealth publishes a consolidated and audited Annual Report on an annual basis, a consolidated Interim Report for its June 30 half-year financial figures, and business/financial updates at the end of Q1 and Q3. Furthermore, for the Annual General Shareholders’ Meeting, the company also publishes the non-consolidated Belgian-GAAP financial statements of the parent company. Prior to October 5, 2010, MDxHealth operated under the name OncoMethylome Sciences.

Statutory Auditor

The statutory mandate of BDO Bedrijfsrevisoren CVBA expires at the 2017 Annual General Shareholders’ meeting approving the financial statements for the year ended December 31, 2016. MDxHealth organizes a tender to appoint a statutory auditor for a period of three years ending on the date of the Annual General Shareholders’ Meeting approving the financial statements for the year ending December 31, 2019. Interested audit firms are invited to address their candidacy by March 10, 2017 to info@mdxhealth.com to obtain the specifications and time schedule for introducing a proposal.

Reporting Calendar

  • Publication Top line 2016 results : January 9, 2017
  • Publication 2016 FY results: February 23, 2017
  • Publication of first interim trading update: May 8, 2017
  • Publication H1 results: August 31, 2017
  • Publication of second interim trading update: November 2, 2017

 

 

3-year Snapshot    
Condensed Consolidated Statement of Comprenhsive Income
In '000 of USD 2016 2015 2014
Revenues 29,970 17,640 11,671
Gross Profit 19,867 10,735 5,218
Research and Development Expenses 1,977 3,257 2,376
Selling, General and Adminisitrative Expenses 30,953 22,358 18,321
Other Operating (Income)/Expenses 217 498 139
Other Profit/(Loss)(Ebit) -12,846 -14,382 -15,342
Financial Income 36 13 109
Financial Expenses 477 104 23
Income Taxes -113 - -
Net Profit/(Loss -13,147 -14,473 -15,256
       
Consolidated Statement of Financial Position
In '000 of USD      
Assets 2016 2015 2014
Total Non-Current Assets 16,233 13,096 2,840
Total Current Assets 51,488 44,646 28,113
Of Which Cash and Cash Equivalents 30,871 31,680 18,897
Total Assets 67,721 57,742 30,953
       
Liabilities and Shareholders’ Equity      
Total Equity 52,741 44,262 23,776
Non-Current Liabilities 2,387 2,655 83
Current Liabilities 12,593 10,825 7,094
       
Consolidated Cash Flow Statement      
In '000 of USD 2016 2015 2014
Operating Cash Flow -16,585 -14,394 -18,513
Investing Cash Flow -5,316 -7,576 -1,256
Financing Cash Flow 21,095 35,042 14,666
Net Change in Cash and Cash Equivalents -806 13,072 -5,103
Cash and Cash Equivalents at End of Period 30,871 31,680 18,897

Financial Reports

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

  • Full year 2006 Registration Document (Annual Report): english français
  • 2006 Full Year Results: english français
  • 2006 Full Year Results Financial Report: english
  • Statutory Statements with Reports of Board and Auditor: english
  • 2006 Half year Report (June 30 figures): français